PONATINIB FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA AND PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

被引：6

作者：

Narayanan, V. ^{[1
]}

Pollyea, D. A. ^{[1
,2
]}

Gutman, J. A. ^{[1
,2
]}

Jimeno, A. ^{[1
,2
]}

机构：

[1] Univ Colorado, Sch Med, Dept Med, Div Med Oncol, Aurora, CO 80045 USA

[2] Univ Colorado, Sch Med, Dev Therapeut Program, Aurora, CO 80045 USA

来源：

DRUGS OF TODAY | 2013年 / 49卷 / 04期

关键词：

Ponatinib; Chronic myeloid leukemia; Acute lymphoblastic leukemia; Tyrosine kinase inhibitor; T315I mutation; CHRONIC MYELOGENOUS LEUKEMIA; PATIENTS RECEIVING IMATINIB; KINASE DOMAIN MUTATIONS; ABL TYROSINE KINASE; CHRONIC-PHASE; CANCER STATISTICS; FOLLOW-UP; INHIBITOR; RESISTANCE; GENE;

D O I：

10.1358/dot.2013.49.4.1950147

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Ponatinib is a novel, next-generation, small-molecule tyrosine kinase inhibitor with potent activity against the BCR-ABL fusion oncogene as well as all other ABL kinase domain mutations that confer resistance to earlier generation tyrosine kinase inhibitors. Due to its unique structure, it is the only tyrosine kinase inhibitor with the capability to counter the highly resistant T315I or gate-keeper mutation in leukemic cells that express the Philadelphia chromosome. This review will focus on the preclinical pharmacology, pharmacokinetics and clinical utility of ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive adult acute lymphoblastic leukemia.

引用

页码：261 / 269

页数：9

共 43 条

[1]

[Anonymous], BLOOD

[2]

[Anonymous], 2012, Highlights of prescribing information, Lucentis (Genentech) [Internet]

[3]

Bixby Dale, 2009, Hematology Am Soc Hematol Educ Program, P461, DOI 10.1182/asheducation-2009.1.461

[4]

Cassuto O, 2012, ONCOTARGET, V3, P1557

[5] Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation [J].

Cortes, Jorge ;

Lipton, Jeff H. ;

Rea, Delphine ;

Digumarti, Raghunadharao ;

Chuah, Charles ;

Nanda, Nisha ;

Benichou, Annie-Claude ;

Craig, Adam R. ;

Michallet, Mauricette ;

Nicolini, Franck E. ;

Kantarjian, Hagop .

BLOOD, 2012, 120 (13) :2573-2580

[6]

Cortes JE, 2012, J CLIN ONCOL, V30

[7] Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias [J].

Cortes, Jorge E. ;

Kantarjian, Hagop ;

Shah, Neil P. ;

Bixby, Dale ;

Mauro, Michael J. ;

Flinn, Ian ;

O'Hare, Thomas ;

Hu, Simin ;

Narasimhan, Narayana I. ;

Rivera, Victor M. ;

Clackson, Tim ;

Turner, Christopher D. ;

Haluska, Frank G. ;

Druker, Brian J. ;

Deininger, Michael W. N. ;

Talpaz, Moshe .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (22) :2075-2088

[8] Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial [J].

Cortes, Jorge E. ;

Kim, Dong-Wook ;

Kantarjian, Hagop M. ;

Bruemmendorf, Tim H. ;

Dyagil, Irina ;

Griskevicius, Laimonas ;

Malhotra, Hemant ;

Powell, Christine ;

Gogat, Karin ;

Countouriotis, Athena M. ;

Gambacorti-Passerini, Carlo .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (28) :3486-3492

[9] INDUCTION OF CHRONIC MYELOGENOUS LEUKEMIA IN MICE BY THE P210BCR/ABL GENE OF THE PHILADELPHIA-CHROMOSOME [J].

DALEY, GQ ;

VANETTEN, RA ;

BALTIMORE, D .

SCIENCE, 1990, 247 (4944) :824-830

[10] Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis [J].

de Lavallade, Hugues ;

Apperley, Jane F. ;

Khorashad, Jamshid S. ;

Milojkovic, Dragana ;

Reid, Alistair G. ;

Bua, Marco ;

Szydlo, Richard ;

Olavarria, Eduardo ;

Kaeda, Jaspal ;

Goldman, John M. ;

Marin, David .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (20) :3358-3363

← 1 2 3 4 5 →